It was developed at Monash University in Australia and taken through clinical work in the early 2000s as an obesity research candidate
BATOONI SYRUP - For Delayed Speech & Stammering in Children BICODIS-AC SYRUP - Calcium Carbonate (80mg) + Sodium Alginate (250mg) + Sodium Bicarbonate (133.5mg) BIODEX A SYRUP BIODEX PLUS SYRUP BIODEX SYRUP - Bromhexine 2mg + Guaiphenesin 50mg + Terbutaline Sulphate 1.25mg Syrup Base /5ml BECLOSAFE SYRUP CITSAFE AM SYRUP BELL OK Z DRY SYRUP - Streptococcus Faecalis 50 Million + Clostridium Butyricum 5 Million + Bacillus Mesentericus 2 Million+ Lactic Acid Bacillus (lactobacillus Sporogenes) 100 Million + Fructo-oligosaccharide (fos) 50 Million+ Zinc 5 Million CRANOSAFE SYRUP - Cranberry 200mg,d-mannose 300mg & Potassium Magnesium Citrate 978mg Syrup CYPTOMAC SYRUP - Cyproheptadine (2mg5ml) + Tricholine Citrate (275mg5ml) + Flavored Sorbitol Base CEFTIGEST CV 50 DRY SYRUP -Cefixime (50mg) + Clavulanic Acid (31.25mg) CEFTIGEST O DRY SYRUP - CEFIXIME 50MG +OFLOXACIN 50MG DRY SYRUP CEFTROPIC 100 DRY SYRUP - Cefpodoxime Proxetil (100mg/5ml) CEFTROPIC 50 DRY SYRUP CEFTROPIC XP 100 DRY SYRUP - Cefpodoxime Proxetil (100mg) + Clavulanic Acid (62.50mg) DEFLOPAM SUSPENSION - DEFLAZACORT 6MG SUSPENSION CEFTROPIC XP 50 DRY SYRUP - Cefpodoxime Proxetil (50mg) + Clavulanic Acid (31.25mg) CETVIN PLUS JUNIOR SUSPENSION - Each 5 Ml Contains : Paracetamol Ip 250 Mg, Chlorpheniramine Maleate Ip 2 Mg , Phenylphrine Hydrochloride Ip 5 Mg , In A Flavoured Syrupy Base Q.s
Comparative Clinical Efficacy Data AOD-9604 Clinical Development History AOD-9604 underwent clinical development by Metabolic Pharmaceuticals (Australia) in the early 2000s: Phase 1: Demonstrated safety and tolerability in healthy volunteers Phase 2a: Showed modest trends toward fat loss in small cohorts Phase 2b (2007): A larger trial of 536 obese participants failed to demonstrate statistically significant weight loss versus placebo after 24 weeks of treatment Development Discontinued: Following Phase 2b failure, clinical development was halted Semaglutide Clinical Evidence The STEP trial program represents the most comprehensive obesity treatment evidence: STEP 1: 14.9% weight loss vs 2.4% placebo at 68 weeks (n=1,961) STEP 2: 9.6% weight loss in type 2 diabetes patients STEP 3: 16.0% weight loss with intensive behavioral therapy STEP 4: Weight maintenance confirmed with continued treatment SELECT: 20% reduction in major cardiovascular events Evidence Quality Comparison The evidence gap is substantial: Semaglutide: Multiple large Phase 3 trials, FDA approval, real-world data, cardiovascular outcomes AOD-9604: Failed Phase 2b, no Phase 3 completion, no regulatory approval for obesity Safety and Tolerability Profile AOD-9604 Safety Profile: Generally Well-Tolerated: Phase 1/2 trials showed favorable safety No Metabolic Disruption: Did not affect blood glucose, insulin, or IGF-1 levels No GH-Related Effects: No fluid retention, joint pain, or tissue growth seen with full GH Limited Data: Lack of Phase 3 and long-term safety information Semaglutide Safety Profile: GI Events: Nausea (44%), diarrhea (31%), vomiting (24%)typically transient Serious AEs: Pancreatitis risk, gallbladder disease (similar to other weight loss) Boxed Warning: Thyroid C-cell tumors (rodent studies
Inadequate protein intake can paradoxically increase hunger
It helps convert carbohydrates and fats into glucose, which is used for energy
research-amq-06 Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
